New data shows nipocalimab’s effectiveness in reducing autoantibodies in Sjögren’s disease
Johnson & Johnson has unveiled compelling new data at a recent medical conference, highlighting the effectiveness of nipocalimab in reducing the autoantibodies responsible for Sjögren’s